Ventricular Septal Defect (VSD) is a congenital anomaly affecting the heart, distinguished by an abnormal opening in the ventricular septum—the wall that separates the heart's lower chambers. This condition results in a direct pathway for blood to traverse from the left ventricle to the right ventricle, disrupting the typical flow of oxygenated and deoxygenated blood. Classified among the prevalent congenital heart defects, VSDs exhibit variability in size and severity. Smaller defects might exhibit a tendency to close spontaneously, while larger ones may necessitate medical intervention. The manifestations of VSD can span from mild to severe, encompassing symptoms such as feeding difficulties, inadequate weight gain, and respiratory challenges. Early detection of VSD is critical, as timely management, comprising either pharmaceutical interventions or surgical procedures, is pivotal for addressing the condition and fostering optimal cardiac function. Sustaining proper cardiac health throughout life requires regular monitoring and follow-up care for individuals diagnosed with VSD.
Title : Personalized and precision medicine (PPM) as a unique healthcare model through biodesign-driven translational applications and cardiology-related healthcare marketing to secure the human healthcare and biosafety
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Beyond weight loss and diabetes control GLP 1 agonists paradigm shift in Cardiovascular care .
Syed Raza, Awali Hospital, Bahrain
Title : Vericiguat Inhibits the Progress of Cardiac Hypertrophy and Prevents Hypertrophy Induced Heart Failure by Multiple Mechanisms
Guo Wei He, TEDA International Cardiovascular Hospital, Tianjin University, China
Title : Coronary revascularization in patients with diabetes: Prospects for stenting in patients with type 1 diabetes and coronary artery disease
Mekhman N Mamedov, National Research Center for Therapy and Preventive Medicine, Russian Federation
Title : STEMI versus acute occlusive myocardial infarction: Which term should we use?
Yochai Birnbaum, Baylor College of Medicine, United States
Title : Chronic angina and the health economics of cardiovascular risk reduction in macro- and microvascular coronary disease
Uwe Peter Tigor, Auxilius Pharma, United States